gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Somatostatin receptor 2

SSTR2, somatostatin receptor 2, somatostatin receptor type 2, somatostatin receptor subtype 2
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biologic effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: somatostatin, SSTR5, somatostatin receptor, CAN, V1a
Papers on SSTR2
Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
New
Lee et al., Seoul, South Korea. In Pancreas, Feb 2016
The SSTR2(+) and SSTR5(+) groups had better prognosis than the SSTR2(-) (P = 0.009) and SSTR5(-) groups (P = 0.03), respectively.
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
New
De Marinis et al., Manchester, United Kingdom. In Eur J Endocrinol, Feb 2016
Tumours with low AIP displayed reduced SSTR2 (SSTR2a scores 0-1 44.4 vs 6.7%; P=0.006) while no difference was seen in SSTR5 (SSTR5 scores 0-1 33.3 vs 23.3%; P=0.55).
Comprehensive Profiling of GPCR Expression in Ghrelin-producing Cells.
New
Nakao et al., Ōsaka, Japan. In Endocrinology, Jan 2016
Expression levels of GPCRs previously suggested to regulate ghrelin secretion including adrenergic β1 receptor, GPR81, oxytocin receptor, GPR120, and somatostatin receptor 2 were high in MGN3-1 cells.
Expression profiles of somatostatin, dopamine, and estrogen receptors in pituitary adenomas determined by means of synthetic multilocus calibrators.
New
Cap et al., Hradec Králové, Czech Republic. In Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, Dec 2015
In growth hormone-secreting adenomas, D2R and SSTR2 transcripts were extensively expressed, followed by ER1, SSTR5, SSTR3, and SSTR1.
Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas.
New
Atsumi et al., Sapporo, Japan. In Endocr J, Dec 2015
UNASSIGNED: We investigated the relationship between the results of the octreotide test and somatostatin receptor (SSTR) 2 expression in insulinoma patients, to evaluate the usefulness of this test for predicting SSTR2 expression in insulinomas in Japanese patients.
Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.
New
Uslu et al., İzmir, Turkey. In Tumour Biol, Dec 2015
To enlighten the action mechanisms of the combination treatment, expression levels of somatostatin receptors 2 and 5 (SSTR2 and SSTR5) were also investigated.
Comparison of the therapeutic response to treatment with a 177-lutetium labeled somatostatin receptor agonist and antagonist in preclinical models.
New
de Jong et al., Bronkhorstspruit, South Africa. In J Nucl Med, Nov 2015
METHODS: We analyzed radiotracer uptake (both membrane-bound and internalized fractions) and the produced DNA double strand breaks, by determining the number of p53 binding protein 1 (53BP1) foci, after incubating SSTR2 positive cells with (177)Lu-DTPA, (177)Lu-DOTA-octreotate or (177)Lu-DOTA-JR11.
The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior.
Review
New
Taché et al., Berlin, Germany. In Horm Behav, Jul 2015
Interestingly, in contrast to the predominantly inhibitory actions of peripheral somatostatin, the activation of brain sst2 signaling by intracerebroventricular injection of stable somatostatin agonists potently stimulates food intake and independently, drinking behavior in rodents.
Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.
Oliveira et al., Rio Grande, Brazil. In Int J Clin Exp Pathol, 2014
All five SSTRs were expressed in our sample, at frequencies ranging from 61.6 to 100%, with a predominance of SSTR2.
Somatostatin receptor based imaging and radionuclide therapy.
Review
Zhang et al., Hangzhou, China. In Biomed Res Int, 2014
Five distinct subtypes (termed SSTR1-5) have been identified, with SSTR2 showing the highest affinity for natural SST and synthetic SST analogs.
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
Review
Berruti et al., Brescia, Italy. In Expert Opin Investig Drugs, 2014
The strength of these drugs has been their specificity for somatostatin receptor subtype 2. However, this peculiarity may become a weakness in some patients with tumors harboring somatostatin receptors different from the subtype 2. Another clinically relevant aspect related to the use of octreotide LAR and lanreotide ATG is the burden of injectable drug regimen that may adversely impact the quality of life of patients with acromegaly and NETs.
Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.
Review
Coy et al., Hengyang, China. In Curr Top Med Chem, 2014
Lanreotide is a synthetic, long-acting SST analog with high binding affinity to SSTR2, and has been clinically approved for the treatment of acromegaly due to excessive growth hormone.
Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation.
Review
Mantovani et al., Milano, Italy. In Horm Metab Res, 2014
Resistance has been associated with defective expression of functional somatostatin and dopamine receptors SSTR2, SSTR5, and DRD2, respectively.
Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.
GeneRIF
Rogers et al., Saint Louis, United States. In Endocrinology, 2012
Data show that the aspartic acid changes at position 89 to either Ala, Leu, or Arg generated mutant somatostatin receptor subtype 2 (SSTR2) with varying expression profiles and a complete inability to bind somatostatin-14 (SST).
Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia.
GeneRIF
Bagnoli et al., Pisa, Italy. In Naunyn Schmiedebergs Arch Pharmacol, 2012
sst2 may protect retinal cells from hypoxia, thus implementing the background to establish potential pharmacological targets.
Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
GeneRIF
Mercado et al., Mexico. In J Clin Endocrinol Metab, 2012
Determination of the expression of SSTR2 in an attempt to establish correlations and/or associations with clinical characteristics of patients with nonfunctioning pituitary adenomas.
Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma.
GeneRIF
Marchetti et al., Roma, Italy. In Anticancer Res, 2012
High somatostatin receptor 2 is associated with gastric adenocarcinoma.
The somatostatinergic system in the mammalian cochlea.
GeneRIF
Bodmer et al., Basel, Switzerland. In Bmc Neurosci, 2010
somatostatin receptors demonstrate specific expression in HCs and supporting cells of the mouse cochlea, and that absence of SST1 alters the expression of SST2.
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.
Impact
Scarpa et al., Verona, Italy. In J Clin Oncol, 2010
RESULTS: Our data showed that: tuberous sclerosis 2 (TSC2) and phosphatase and tensin homolog (PTEN) were downregulated in most of the primary tumors, and their low expression was significantly associated with shorter disease-free and overall survival; somatostatin receptor 2 (SSTR2) was absent or very low in insulinomas compared with nonfunctioning tumors; and expression of fibroblast growth factor 13 (FGF13) gene was significantly associated with the occurrence of liver metastasis and shorter disease-free survival.
Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Impact
Buscail et al., Toulouse, France. In J Clin Oncol, 2008
The tracer uptake (positive (111)In-pentetreotide scintigraphy) correlated with the tumor expression of somatostatin receptor sst2 (P < .001)
share on facebooktweetadd +1mail to friends